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Lisa C. Richardson, MD, MPH, Christopher S. Parker, PhD, MPH, James Tsai, MD, MPHMillions of people in the U.S. are affected byblood disorders.1 The accumulating epide-miologic evidence for non-malignant blood
disorders continues to strengthen its consideration as a
national public health priority. Although there is
enormous potential for public health practice to reduce
the disease burden and associated healthcare costs, the
ﬁscal resources with which to do so are decreasing and
may continue in the near future. Thus, the Division of
Blood Disorders (DBD) at the Centers for Disease
Control and Prevention (CDC) has embraced a new
currency of developing and implementing a comprehen-
sive set of public health approaches to effectively promote
and improve the health of people with blood disorders.
In spite of having effective regimens to prevent blood
clots, it is estimated that thousands of patients will die
of a blood clot associated with a hospital stay.2 Hydro-
xyurea has been proven to result in fewer painful crises,
fewer episodes of acute chest syndrome, fewer blood
transfusions,3 and lower risk of death in adult sickle cell
disease (SCD) patients,4 yet less than one third of the
patients who might beneﬁt from it actually receive it.5
Prophylactic treatment in hemophilia patients reduces the
number of bleeds signiﬁcantly as compared to on-
demand treatment; however, this has not become a
standard of care.6 These public health activities have been
undertaken by DBD and seek to bring to bear proven
interventions in areas where research and surveillance
ﬁndings suggest that potential beneﬁts might be realized
and adverse effects might be mitigated. Additionally,
these approaches attempt to develop and implement
interventions that beneﬁt the entire community of people
affected by blood disorders.
This is the third special set of articles published by the
American Journal of Preventive Medicine describing and
highlighting the unique challenges and opportunities for
public health to positively impact the health and care of
people affected by a blood disorder. In this theme issue,
the DBD details its work in meeting the emerging public
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of those affected by a blood disorder, ﬁrst by supporting
public health practice activities directed to people with
hemophilia, and subsequently by expanding to serve
people with other nonmalignant blood disorders.7 These
articles communicate the DBD’s efforts to develop
surveillance systems to provide data for action and
monitoring interventions.8 Further, they also illustrate
the use of data used in decision making to improve the
lives of people with blood disorders.9,10
The DBD is committed to serving those affected by a
blood disorder, whether inherited (e.g., hemophilia and
SCD) or acquired (venous thromboembolism). No single
entity or organization alone will be able to accomplish
the objectives of improving quality and length of life for
these special populations. This special theme focus
affords an important opportunity to communicate the
Division’s ongoing efforts to a wider audience with the
goal to align, leverage, and synergize our work with that
of others in the ﬁeld. In collaboration with our many
public health partners—other federal and state agencies,
academia, and professional and community-based orga-
nizations—the DBD at CDC works to improve the lives
of people at risk of or affected by a blood disorder.
Through public health practice, the DBD is ensuring that
evidence is put into practice to improve health outcomes
for the populations it serves.
The ﬁndings and conclusions in this report are those of the
authors and do not necessarily represent the ofﬁcial position of
CDC.
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